Srikala S Sridhar
Overview
Explore the profile of Srikala S Sridhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
4410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury D, Apolo A, Jiang D, Skinner E, Chisolm S, Bangs R, et al.
BJU Int
. 2025 Mar;
PMID: 40047292
Objectives: To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for...
2.
ODwyer R, Junker S, Szulkin R, Kienzle S, Kearney M, Sridhar S
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941876
Background: For many decades, gemcitabine + cisplatin has been a preferred and accepted treatment option for patients with urothelial cancer (UC). In patients ineligible for standard-dose cisplatin, split-dose cisplatin is...
3.
Kulkarni G, Black P, Sridhar S, Zlotta A, Shayegan B, Rendon R, et al.
Can Urol Assoc J
. 2025 Feb;
19(1):E1-E16.
PMID: 39899885
No abstract available.
4.
Powles T, Park S, Gurney H, Loriot Y, Sridhar S, Bellmunt J, et al.
Future Oncol
. 2025 Jan;
21(4):381-391.
PMID: 39815416
No abstract available.
5.
Stecca C, Chowdhury D, Blais N, Alimohamed N, Wood L, Canil C, et al.
Can Urol Assoc J
. 2024 Dec;
18(12):379-390.
PMID: 39641956
No abstract available.
6.
Siefker-Radtke A, Huddart R, Bilen M, Balar A, Castellano D, Sridhar S, et al.
Urol Oncol
. 2024 Oct;
PMID: 39477771
Background: In PIVOT-02, bempegaldesleukin (BEMPEG), a pegylated interleukin-2 cytokine prodrug, in combination with nivolumab (NIVO), a Programmed cell death protein 1 inhibitor, demonstrated the potential to provide additional benefits over...
7.
Stecca C, Abdeljalil O, Sridhar S
Clin Genitourin Cancer
. 2024 Oct;
22(6):102215.
PMID: 39353213
Introduction: Bone metastases (BM) in metastatic urothelial carcinoma (mUC) may impact patient outcomes, but their independent effect with immune checkpoint inhibitors (ICIs) is uncertain. We aimed to assess the impact...
8.
Wong B, Peng J, Jiang D, Fizazi K, Powles T, James N, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102210.
PMID: 39299034
Background: Clinical trials are categorized as industry sponsored trials (ISTs) or investigator-initiated trials (IITs) based on the source of funding and sponsor of the trial. ISTs are usually run by...
9.
ODwyer R, Musat M, Gulas I, Hubscher E, Moradian H, Guenther S, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102176.
PMID: 39260094
Background: Gemcitabine plus cisplatin (GC) is a highly active and commonly used regimen in locally advanced/metastatic urothelial carcinoma (la/mUC). With GC, cisplatin is dosed at 70 mg/m on day 1...
10.
Zhang T, Tan A, Shah A, Iyer G, Morris V, Michaud S, et al.
Oncologist
. 2024 Aug;
29(12):1003-1013.
PMID: 39167703
Platinum-based chemotherapy has been the standard first-line (1L) treatment for advanced urothelial carcinoma (UC) for decades, based on the proven efficacy and established safety profiles of cisplatin- and carboplatin-based regimens....